AMYT News and Press, Amryt Pharma plc From 01/12/23

Summary Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones. Amryt Pharma achieved its sales target in the highly competitive market for rare disease the...

NEW YORK, NY / ACCESSWIRE / January 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Safehold Inc. (NYSE:SAFE)'s merger ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are acquisition deals, clinica...

Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma ( NASDAQ: AMYT ) for total transaction value of ~$1.25B in upfront consideration, representing a 107% premium to Amryt ADS' closing price on January 6, 2023, plus CVRs representing an additional ~ $225M of potential consideration. ...

Chiesi Farmaceutici S.p.A . to Acquire Amryt Pharma Plc - Transaction expand s Chiesi’s rare disease medicine portfolio - All c ash acquisition at US$14.50 per ADS , plus C ontingent V alue R ight...

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5 , 202 3 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...

COMP A dopts P ositive O pinion on O rphan D esignation for Mycapssa® for the T reatment of C arcinoid S yndrome A ssociated with N euroendocrine T umors DUBLIN, Ireland, and Boston MA, Decemb...

European Commission approves Mycapssa ® for the t reatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, ...

Summary Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open wounds. Currently, there are three potential DEB treatments that have co...

Amryt Pharma press release ( NASDAQ: AMYT ): Q3 GAAP EPS of -$0.06. Revenue of $61.1M (+8.1% Y/Y). FY 2022 revenue guidance of $260M - $270M reaffirmed, representing 17-21% growth over 2021 For further details see: Amryt Pharma GAAP EPS of -$0.06, revenue of ...